| Literature DB >> 35695458 |
Karin Hjort1, Elin Fermér1, Po-Cheng Tang1, Dan I Andersson1.
Abstract
The use and misuse of antibiotics have resulted in the selection of difficult-to-treat resistant bacteria. Two key parameters that influence the selection of resistant bacteria are the minimal selective concentration (MSC) and the fitness cost of resistance, both of which have been measured during planktonic growth in several studies. However, bacterial growth most often occurs in biofilms, and it is unclear if and how these parameters differ under these two growth conditions. To address this knowledge gap, we compared a selection of several types of antibiotic-resistant Escherichia coli mutants during planktonic and biofilm growth to determine the fitness costs and MSCs. Biofilm-forming Escherichia coli strains are commonly found in catheter-associated and recurrent urinary tract infections. Isogenic strains of a biofilm-forming E. coli strain, differing only in the resistance mechanisms and the fluorescent markers, were constructed, and susceptible and resistant bacteria were grown in head-to-head competitions at various concentrations of antibiotics under planktonic and biofilm conditions. Mutants with resistance to five different antibiotics were studied. The results show that during both planktonic and biofilm growth, selection for the resistant mutants occurred for all antibiotics at sub-MICs far below the MIC of the antibiotic. Even though differences were seen, the MSC values and the fitness costs did not differ systematically between planktonic and biofilm growth, implying that despite the different growth modes, the basic selection parameters are similar. These findings highlight the risk that resistant mutants may, similarly to planktonic growth, also be selected at sub-MICs of antibiotics in biofilms. IMPORTANCE Our understanding of how and where antibiotic resistance is selected in response to antibiotic exposure is still limited, and this is particularly true for selective processes when bacteria are growing in biofilms, arguably the most significant mode of growth of bacteria in human and animal infections as well as in other settings. In this study, we compared how different types of resistant E. coli strains were selected in response to antibiotic exposure during planktonic and biofilm growth. Determination of the minimal selective concentrations (MSCs) and fitness costs of resistance showed that they were comparable under these two different conditions, even though some differences were observed. Importantly, the MSCs were far below the MICs for all mutants under both planktonic and biofilm growth, emphasizing the significance of low antibiotic concentrations in driving the emergence and enrichment of resistant bacteria.Entities:
Keywords: Escherichia coli; antibiotic resistance; biofilms; fitness; minimal selective concentration; planktonic
Mesh:
Substances:
Year: 2022 PMID: 35695458 PMCID: PMC9239065 DOI: 10.1128/mbio.01447-22
Source DB: PubMed Journal: mBio Impact factor: 7.786
FIG 1Schematic overview of the method to determine fitness costs and minimal selective concentrations (MSCs). Cultures of isogenic susceptible and resistant fluorescent strains were grown overnight separately and then mixed. (A) Fitness cost and MSC determinations during biofilm growth. FlexiPegs were inserted into a mix of fluorescent susceptible and resistant bacteria. After 3 h of incubation, the biofilm was extracted from a subset of the FlexiPegs to determine the initial ratio between susceptible and resistant strains before antibiotics were added (time point 0). The remaining FlexiPegs were transferred to different antibiotic concentrations and further incubated. To reduce the potential interference of planktonic cells, the biofilms on the FlexiPeg were briefly dipped into PBS every hour before they were transferred into fresh medium with or without antibiotics. After 9 h of incubation, the biofilm was harvested, and the ratios of susceptible to resistant fluorescently labeled bacteria were determined by flow cytometry at time points 0 and 1 (representing approximately 8 generations of biofilm growth). (B) Fitness cost and MSC determinations during planktonic growth. A mix of susceptible and resistant bacteria was transferred to different antibiotic concentrations for incubation, generating 10 generations of growth. Bacteria were analyzed by flow cytometry to determine the ratio between fluorescently labeled susceptible and resistant bacteria for each antibiotic concentration and time point (10, 20, and 30 generations). (C) Calculation of selection coefficients. The ratios of resistant to susceptible bacteria measured at different antibiotic concentrations were plotted over time to obtain the selection coefficients (slope of the curves). (D) Calculations of fitness costs and MSCs. The fitness costs and MSCs were estimated by plotting the selection coefficient (panel C) as a function of the antibiotic concentration (AB). The intercept with the x axis is the MSC value, and the intercept with the y axis is the fitness cost.
FIG 2Determination of fitness costs and MSCs for different resistant mutants and antibiotics. Selection coefficients obtained from competitions between susceptible and resistant bacteria (see Fig. S1 and S3 in the supplemental material) were plotted as a function of the antibiotic concentration for planktonic and biofilm growth. Standard errors of the means are from two independent experiments with four biological replicates and a dye swap, for 16 samples in total for planktonic growth, and with three biological replicates and a dye swap, for 6 samples in total for biofilm growth. Resistant mutants were E. coli rpsL K42R (A), E. coli rpsL K42N (B), E. coli rpoB S531L (C), E. coli bgl::dfr (D), E. coli uhpT STOP 5 aa (E), and E. coli ΔnfsAB (F).
MICs, minimal selective concentrations, and fitness costs for resistant mutants during planktonic and biofilm growth
| Resistance | Resistance mutation | Planktonic growth | Biofilm growth | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIC mg/L for susceptible strain | Fitness cost (%) | SEM of fitness cost (%) | MSC (mg/L) | SEM of MSC (mg/L) | MIC/MSC ratio | MBIC mg/L for susceptible strain | Fitness cost (%) | SEM of fitness cost (%) | MSC (mg/L) | SEM of MSC (mg/L) | MBIC/MSC ratio | ||
| Streptomycin | 48 | 17.8 | 0.5 | 3.1 | 0.06 | 15 | 96 | 22 | 2.5 | 5.9 | 0.6 | 15 | |
| Streptomycin | 48 | 2.4 | 0.5 | 0.3 | 0.03 | 160 | 96 | 9.6 | 0.8 | 2.2 | 0.2 | 44 | |
| Rifampicin | 24 | 18 | 0.8 | 1.1 | 0.03 | 22 | >384 | 37.4 | 1.9 | 1.5 | 0.08 | >256 | |
| Nitrofurantoin | Δ | 32 | 1.4 | 0.4 | 0.4 | 0.08 | 80 | 256 | ND | ND | ND | ||
| Trimethoprim | 1 | 1 | 0.3 | 0.017 | 0.003 | 50 | >512 | 2.9 | 0.9 | 0.023 | 0.008 | >25,000 | |
| Fosfomycin | 32 | 2.9 | 0.7 | 0.4 | 0.06 | 80 | 512 | 2.8 | 0.7 | 1.2 | 0.1 | ND | |
ND, the fitness cost or MSC value could not be determined; MBIC, minimal biofilm inhibitory concentration measured after 24 h; MSC, minimal selective concentration; MIC, minimal inhibitory concentration; SEM, standard error of the mean.
FIG 3Antibiotic tolerance measured as the minimal biofilm inhibitory concentration (MBIC). The MBIC was determined after 24 h of biofilm formation in brain heart infusion medium. The biofilm was pregrown for 24 h before antibiotics were added. The biofilms were harvested after an additional 24 h of incubation with antibiotic exposure. Data are the medians from 4 to 8 biological replicates.
MICs and minimal biofilm inhibitory concentrations for resistant mutants
| DA no. | Genotype | Streptomycin | Rifampicin | Nitrofurantoin | Trimethoprim | Fosfomycin | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| MIC mg/L | MBIC mg/L 24 h in BHI | MIC mg/L | MBIC mg/L 24 h in BHI | MIC mg/L | MBIC mg/L 24 h in BHI | MIC mg/L | MBIC mg/L 24 h in BHI | MIC mg/L | MBIC mg/L 24 h in BHI | ||
| DA58419 | 48 | 96 | 24 | >384 | 32 | 256 | 1 | >512 | 32 | 512 | |
| DA58420 | 48 | 96 | 24 | >384 | 32 | 256 | 1 | >512 | 32 | 512 | |
| DA66038 | >1,536 | ND | |||||||||
| DA66039 | >1,536 | ND | |||||||||
| DA71952 | >1,536 | ND | |||||||||
| DA71953 | >1,536 | ND | |||||||||
| DA66034 | >384 | ND | |||||||||
| DA66035 | >384 | ND | |||||||||
| DA69418 | 128 | ND | |||||||||
| DA69419 | 128 | ND | |||||||||
| DA71530 | >2,048 | ND | |||||||||
| DA71531 | >2,048 | ND | |||||||||
| DA66040 | 1,024 | ND | |||||||||
| DA66041 | 1,024 | ND | |||||||||
BMD, broth microdilution; MBIC, minimal biofilm inhibitory concentration; BHI, brain heart infusion medium; ND, not determined; MIC, minimal inhibitory concentration.
Comparison of minimal selective concentrations determined under different growth conditions and in different experimental systems
| Antibiotic | Exptl setup | Gene location | Gene(s) analyzed | Planktonic MSC | Biofilm MSC | Reference |
|---|---|---|---|---|---|---|
| Trimethoprim | Competition, | Chromosomal | 17 μg/L | 23 μg/L | This study | |
| Competition, | Chromosomal | <2 μg/L |
| |||
| Competition, | Plasmid | 33 μg/L |
| |||
| Complex bacterial community, different methods of measurement | 31.25–250 μg/L |
| ||||
| Competition, | Plasmid (pMK) | 42–50 μg/L |
| |||
| Biofilm, complex | Trimethoprim-resistant | 10–100 μg/L |
| |||
| Streptomycin | Competition, | Chromosomal | 3.1 mg/L | 5.9 mg/L | This study | |
| Competition, | Chromosomal | 0.3 mg/L | 2.4 mg/L | This study | ||
| Competition, | Chromosomal | 1 mg/L |
| |||
| Biofilm, complex bacterial community | Metagenome | Aminoglycoside resistance genes | 0.1–1 mg/L |
| ||
| Biofilm, complex bacterial community | Streptomycin-resistant bacteria | 1–5 mg/L |
| |||
| Gentamicin | Competition, | Chromosome |
| 0.2 mg/L |
| |
| Competition, | Chromosome |
| 10 mg/L |
| ||
| Kanamycin | Competition, | Chromosome | 0.5 mg/L |
| ||
| Competition, | Chromosome | 7 mg/L |
| |||
| Tetracycline | Competition, | Chromosomal | Tn | 15 μg/L |
| |
| Biofilm, complex bacterial community | Tetracycline-resistant bacteria | 1–10 μg/L |
| |||
| Biofilm, complex bacterial community | Metagenome, qPCR | 1 μg/L |
| |||
| Ciprofloxacin | Competition, | Chromosomal | 0.1 μg/L |
| ||
| Competition, | Chromosomal | 2.5 μg/L |
| |||
| Complex community | Ciprofloxacin-resistant bacteria | 1–5 μg/L |
| |||
| Complex | Ciprofloxacin-resistant | 1–5 μg/L |
| |||
| Biofilm, complex | Ciprofloxacin-resistant | 1–10 μg/L |
| |||
| Biofilm, complex | Metagenome | 1–10 μg/L |
| |||
NOEC (no-observed-effect concentration) to LOEC (lowest-observed-effect concentration); MSC, minimal selective concentration.